Study of Tumor Tissue From Patients With Melanoma Treated on Clinical Trial EST-1690

Molecular Prognostic Factor Analysis in Melanoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00937781

Enrollment

307

Registered

2009-07-13

Start date

2011-02-08

Completion date

2011-08-08

Last updated

2017-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melanoma (Skin)

Keywords

stage III melanoma, recurrent melanoma

Brief summary

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at tumor tissue samples from patients with melanoma treated on clinical trial EST-1690.

Detailed description

OBJECTIVES: * To validate the prognostic role of several biomarkers suggested by gene expression profiling and tissue microarray (TMA) studies (e.g., NCOA3, SPP1, and RGS1) on the outcome associated with melanoma in the EST-1690 cohort using IHC analysis. * To examine the potential predictive role of such biomarkers in patients undergoing adjuvant interferon alfa therapy. * To analyze the correlation between the intensity of biomarker expression and survival of this cohort both in the observation and in the interferon-treated groups. * To examine the prognostic role of these biomarkers on the outcome associated with melanoma in the EST-1690 cohort using quantitative-PCR. * To isolate RNA from the primary specimens from patients enrolled in the EST-1690 cohort to assess the expression of genes suggested by cDNA microarray and IHC analyses (e.g., NCOA3, SPP1, and RGS1) as prognostic or predictive markers. OUTLINE: Samples from the EST-1690 cohort are obtained and analyzed for several biomarkers (i.e., NCOA3, SPP1, and RGS1) via immunohistochemistry and quantitative PCR. RNA is isolated from the specimens to assess gene expression via quantitative PCR.

Interventions

GENETICRNA analysis

GENETICgene expression analysis

GENETICmicroarray analysis

GENETICpolymerase chain reaction

OTHERimmunohistochemistry staining method

OTHERlaboratory biomarker analysis

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Diagnosis of melanoma * No metastatic disease at diagnosis * Treated on protocol EST-1690 * Primary tumor tissue specimens available PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Design outcomes

Primary

Measure	Time frame
Prognostic role of several biomarkers on the outcome associated with melanoma using IHC	1 month

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026